FDA begins hearing on COX-2 drugs

Share this article:
The FDA kicked off the first of three days of advisory committee hearings today probing the safety of COX-2 drugs.
Steven Galson, acting director of the FDA's Center for Drug Evaluation and Research, promised prompt action, saying the agency will make a decision in the next few weeks based on the committees' recommendations. The FDA is not required to accept such recommendations, but generally does.
Galson also reminded the group that COX-2s are important painkillers used widely by people in chronic pain and that it is important to balance the drugs' risks with their benefits.
The committees will hear from government officials, physicians, researchers and the public before voting on recommendations for COX-2s.
The FDA has been criticized for being slow to recognize problems with COX-2s after clinical studies showed an increased risk of heart attack and stroke in users of Merck's Vioxx and Pfizer's Celebrex and Bextra. 
Merck voluntarily withdrew Vioxx in September. Celebrex and Bextra remain on the market.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.